We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Diagnostics Sector Reaches New Peak

By LabMedica International staff writers
Posted on 01 Nov 2015
According to a new healthcare market research report, the 2014 molecular assays sector worldwide reached an estimated USD 6.1 billion as these tests are used in just about every facet of laboratory medicine.

The “World Market for Molecular Diagnostics, 6th Edition” report from Kalorama Information (New York, NY, USA), authored by Kalorama’s lead IVD analyst Shara Rosen, RT, MBA, estimated that molecular diagnostics account for about 10% of the total IVD market and projected that this is still one of the fastest growth segments in clinical diagnostics. More...


"For the past 5 years the number of assays introduced has been growing," said Rosen, "Moreover, growth of this segment is fueled by rising incidence of chronic disorders, and an increasing geriatric population, and adoption of personalized medicines.”

Employing molecular biology techniques, these novel diagnostics are now nearly two decades old. Innovations have transformed diagnostics with new technologies and clinical applications being continually added. Technologies that are part of molecular diagnostics go far beyond first-generation amplification and include (in no particular order): DNA/RNA/miRNA probes, fluorescent in situ hybridization (FISH), biochips, microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays, microfluidics, circulating tumor cells, cell-free nucleic acid, exosomes, nanoprobes, DNA methylation, sequencing of DNA from formalin-fixed tissues, as well as quantitative nucleic acid amplification methods for viral infections, and MALDI-TOF mass spectrometry.

“Molecular diagnostics is rapidly being developed for genetic testing, infectious diseases testing, blood screening, oncology testing, cardiovascular testing, and others," said Rosen. Continued growth is expected and in the next few years a constant stream of test kits for the newest molecular targets will become commercially available. For the next generation of tests for infectious diseases, emerging pathogens, chronic diseases, and oncology, it appears that services from large hospital and private company-sponsored laboratories will prevail, which limits growth potential for commercial products.

Technologies that were used for the Human Genome Project have now become tools that molecular pathologists routinely use to diagnose diseases that had long remained a mystery. This is good for patient care, but sequencing and next generation sequencing-based tests have evolved so quickly that government agencies and payers are scurrying to cope with accompanying regulatory, reimbursement, and ethical issues.

“Only 5 years ago it would have been almost inconceivable that hospital- and government-funded programs would provide whole genome and whole exome sequencing for thousands and even millions of people,” said Rosen.

The report includes market sizing and forecasts for 8 categories of molecular tests as well as several segments. It also contains trend analysis, strategic recommendations, analyst conclusions, and company profiles of over 190 companies.

Related Links:

Kalorama Information
The World Market for Molecular Diagnostics, 6th Edition



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.